ANN ARBOR, Mich., Nov. 9, 2011 /PRNewswire/ -- Adeona
Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative
medicines for serious central nervous system diseases, announced
today that it will hold its third quarter 2011 investor conference
call on Monday, November 14, 2011, at
2:00pm EST. James S. Kuo, M.D., M.B.A., Adeona's Chief
Executive Officer, will provide an overview of the Company's
multiple sclerosis (MS), ALS and Alzheimer's clinical development
programs and commercialization efforts of wellZin™, Adeona's
zinc acetate lozenges for reducing the duration and symptoms of the
common cold. Julie Caudill, Adeona's
Vice President of Finance, will review the Company's financial
results for the third quarter ended September 30, 2011.
Adeona will be joined by special guest, Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department
of Neurology, and Lead Principal Investigator of the ongoing
multi-center clinical trial evaluating Trimesta™ for
relapsing-remitting MS in women. In addition to providing an
overview of the Trimesta clinical trial, Dr. Voskuhl will share her
insights into the mechanism to treat MS patients and will take
questions about her research.
Dr. Voskuhl is the investigator who discovered that the female
sex hormone, estriol, could suppress MS-like symptoms in a mouse
model of the disease. This preclinical research led to a
10-patient clinical study that showed an 82% decrease in brain
lesions over a six month period. This clinical study was
followed by the 150-patient, randomized, double-blind,
placebo-controlled clinical trial of Trimesta that is currently
underway at 15 centers in the United
States. Dr. Voskuhl's preclinical and clinical work has been
scientifically reviewed and awarded over $8
million in grant funding by organizations such as the
National Institutes of Health, the National Multiple Sclerosis
Society and other third party groups.
Interested parties should call toll free 1-800-860-2442 (U.S.)
or 1-866-605-3852 (Canada), or
from outside North America +1
412-858-4600, fifteen minutes before the start of the call to
register and identify themselves as registrants of the 'Adeona'
Conference Call. Any registered caller on the toll free line may
ask to be placed in the queue for the Question & Answer
session. The call will be simulcast on the web at
http://www.videonewswire.com/event.asp?id=83585. If you are unable
to participate during the live conference call, the webcast will be
available for replay at the same URL,
http://www.videonewswire.com/event.asp?id=83585 for 30 days after
the call.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company focused on developing
innovative medicines for the treatment of serious central nervous
system diseases. The Company's strategy is to license product
candidates that have demonstrated a certain level of clinical
efficacy and develop them to a stage that results in a significant
commercial collaboration. Adeona is developing, or has partnered
the development of, drug product candidates to treat multiple
sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and
Alzheimer's disease. The Company is currently preparing to make the
following products commercially available: reaZin™, a
prescription medical food for the dietary management of zinc
deficiency associated with Alzheimer's disease, and
wellZin™, a homeopathic over-the-counter medicine for
reducing the duration and symptoms of the common cold. Adeona also
operates Adeona Clinical Laboratory, a wholly owned clinical
reference laboratory that provides a broad array of chemistry and
microbiology diagnostic tests. For more information, please visit
Adeona's website at www.adeonapharma.com.
This release includes forward-looking statements on Adeona's
current expectations and projections about future events. In some
cases forward-looking statements can be identified by terminology
such as "may," "could," "potential," "continue," "expects,"
"anticipates," "intends," "plans," "believe," "estimates," and
similar expressions. These statements are based upon current
beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict
and include statements regarding the benefits of estriol. The
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
those reflected in Adeona's forward-looking statements include,
among others, a failure of the Dr. Voskuhl's clinical trial to
provide desired results, a failure by us or our collaborators to
initiate clinical trials for our other development programs and
other factors described in Adeona's report on Form 10-K for the
year ended December 31,
2010 and any other filings with the SEC. The
information in this release is provided only as of the date of this
release, and Adeona undertakes no obligation to update any
forward-looking statements contained in this release on account of
new information, future events, or otherwise, except as required by
law.
SOURCE Adeona Pharmaceuticals, Inc.
